18-Apr-2024
United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating
TipRanks (Thu, 18-Apr 12:25 AM ET)
Business Wire (Tue, 16-Apr 7:00 AM ET)
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
Business Wire (Tue, 26-Mar 7:00 AM ET)
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
Business Wire (Mon, 25-Mar 7:00 AM ET)
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
Business Wire (Tue, 5-Mar 6:00 AM ET)
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
Business Wire (Tue, 27-Feb 6:00 AM ET)
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
Business Wire (Wed, 21-Feb 6:00 AM ET)
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
Business Wire (Wed, 21-Feb 5:55 AM ET)
Business Wire (Wed, 14-Feb 6:00 AM ET)
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.
As of April 18, 2024, UTHR stock price climbed to $236.93 with 430,289 million shares trading.
UTHR has a beta of 0.67, meaning it tends to be less sensitive to market movements. UTHR has a correlation of 0.09 to the broad based SPY ETF.
UTHR has a market cap of $11.15 billion. This is considered a Large Cap stock.
Last quarter United Therapeutics reported $615 million in Revenue and $4.36 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.17.
In the last 3 years, UTHR stock traded as high as $283.09 and as low as $158.38.
The top ETF exchange traded funds that UTHR belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
UTHR stock has underperformed the market in the last year with a return of +3.9%, while SPY returned +22.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in UTHR shares. However, UTHR has outperformed the market in the last 3 month and 2 week periods, returning +8.1% and +1.3%, while SPY returned +5.2% and -2.6%, respectively. This indicates UTHR has been having a stronger performance recently.
UTHR support price is $230.68 and resistance is $239.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR stock will trade within this expected range on the day.